GeNeuro presents its 2023 annual results and progresses in its research programs

GeNeuro SA announced its annual results for the year 2023, marked by significant advances in the development of treatments against neuropsychiatric and neurodegenerative diseases. The main point of interest was the completion of recruitment for the GNC-501 phase 2 clinical trial, evaluating temelimab for post-COVID syndromes. This trial is the first in the field of personalized medicine to treat severe neuropsychiatric symptoms linked to long COVID.

Financially, GeNeuro said it had cash of 1.8 million euros at the end of 2023, with financial visibility extended until the third quarter of 2024 thanks to a capital increase of 5 million euros carried out at the end of 2023. first quarter of 2024. Despite reduced cash burn, the company noted an increased net loss to 14.757 million euros in 2023, compared to 12.200 million in 2022.

This post-COVID trial is particularly notable because it is partially funded by the Swiss Federal Office of Public Health and the European Investment Bank, highlighting its importance as a potential response to a serious public health problem. At the same time, GeNeuro continues to develop treatments for multiple sclerosis and amyotrophic lateral sclerosis.